MIRA: MIRA Pharmaceuticals Inc. Earnings per share for the last twelve months

Corporate company logo of MIRA Pharma (MIRA)

MIRA Pharmaceuticals delegates drug development and testing to external contractors, as evidenced by the net income per share over 12 months, where the latest figure stands at -1.39. This model relies on CDMO facilities in Florida for molecule synthesis. However, stringent FDA and DEA oversight limits the commercial potential of their cannabinoid system, creating value trap risks when analyzing the asset.

MIRA MIRA Pharma Net earnings per share for the last 12 months (02/21/2024 - 11/17/2026)

Analytical breakdowns for MIRA Pharma (MIRA)

- current quotes and average value forecast:
Analysis of all company metrics:MIRA Pharma - MIRA
Mass-produced product of MIRA Pharmaceuticals Inc.

MIRA Pharmaceuticals is scaling the development of plant-based non-opioid analgesics while minimizing specific scientific risks. This metric aggregates net income over four quarters divided by the total number of outstanding shares. The investor assesses the real efficiency of capitalization, separating operational resilience from market volatility. The trend of this value determines the pace of innovation monetization. Analyzing the annual earnings per share (EPS) allows for the identification of stagnation or growth in the business's fundamental value.